Fennec Pharmaceuticals (FENC) EPS (Weighted Average and Diluted) (2016 - 2025)
Fennec Pharmaceuticals (FENC) has disclosed EPS (Weighted Average and Diluted) for 15 consecutive years, with -$0.02 as the latest value for Q3 2025.
- For the quarter ending Q3 2025, EPS (Weighted Average and Diluted) rose 88.89% year-over-year to -$0.02, compared with a TTM value of -$0.25 through Sep 2025, down 257.14%, and an annual FY2024 reading of -$0.02, up 96.67% over the prior year.
- EPS (Weighted Average and Diluted) was -$0.02 for Q3 2025 at Fennec Pharmaceuticals, up from -$0.11 in the prior quarter.
- Across five years, EPS (Weighted Average and Diluted) topped out at $0.41 in Q1 2024 and bottomed at -$0.4 in Q4 2022.
- Average EPS (Weighted Average and Diluted) over 5 years is -$0.13, with a median of -$0.16 recorded in 2021.
- Peak annual rise in EPS (Weighted Average and Diluted) hit 278.26% in 2024, while the deepest fall reached 157.14% in 2024.
- Year by year, EPS (Weighted Average and Diluted) stood at -$0.16 in 2021, then plummeted by 150.0% to -$0.4 in 2022, then soared by 75.0% to -$0.1 in 2023, then rose by 20.0% to -$0.08 in 2024, then soared by 75.0% to -$0.02 in 2025.
- Business Quant data shows EPS (Weighted Average and Diluted) for FENC at -$0.02 in Q3 2025, -$0.11 in Q2 2025, and -$0.04 in Q1 2025.